Ireland's Amryt Aiming For Success Stateside

Files For NASDAQ Listing

With two revenue-generating products already on the market and Phase III data pending on Filsuvez for epidermolysis bullosa, CEO Joe Wiley has told Scrip that a US listing will give Amryt more visibility and credibility when it comes to future licensing and acquisition possibilities.

New York
Nasdaq listing will raise the visibility of Amryt • Source: Shutterstock

With its share price nudging 52-week highs and the integration of recently acquired Aegerion Pharmaceuticals Inc. going well, Ireland's Amryt Pharma PLC is now finalizing plans to list on the NASDAQ stock exchange.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rare Diseases

More from Scrip